Express Scripts’ Cost Cap For PCSK9s Applicable To Other Drugs, PBM Says

If PCSK9 spending by Express Scripts clients surpasses the $750m limit set for 2016, the PBM will pick up the excess cost, under a novel drug management arrangement for Repatha and Praluent.